We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cisternal nicardipine for prevention of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a comparative retrospective cohort study.
- Authors
Vandenbulcke, Alberto; Messerer, Mahmoud; Garvayo Navarro, Marta; Peters, David R.; Starnoni, Daniele; Giammattei, Lorenzo; Ben-Hamouda, Nawfel; Puccinelli, Francesco; Saliou, Guillaume; Cossu, Giulia; Daniel, Roy T.
- Abstract
Purpose: Intrathecal vasoactive drugs have been proposed in patients with aneurysmal subarachnoid hemorrhage (aSAH) to manage cerebral vasospasm (CV). We analyzed the efficacy of intracisternal nicardipine compared to intraventricular administration to a control group (CG) to determine its impact on delayed cerebral ischemia (DCI) and functional outcomes. Secondary outcomes included the need for intra-arterial angioplasties and the safety profile. Methods: We performed a retrospective analysis of prospectively collected data of all adult patients admitted for a high modified Fisher grade aSAH between January 2015 and April 2022. All patients with significant radiological CV were included. Three groups of patients were defined based on the CV management: cisternal nicardipine (CN), ventricular nicardipine (VN), and no intrathecal nicardipine (control group). Results: Seventy patients met the inclusion criteria. Eleven patients received intracisternal nicardipine, 18 intraventricular nicardipine, and 41 belonged to the control group. No cases of DCI were observed in the CN group (p = 0.02). Patients with intracisternal nicardipine had a reduced number of intra-arterial angioplasties when compared to the control group (p = 0.03). The safety profile analysis showed no difference in complications across the three groups. Intrathecal (ventricular or cisternal) nicardipine therapy improved functional outcomes at 6 months (p = 0.04) when compared to the control group. Conclusion: Administration of intrathecal nicardipine for moderate to severe CV reduces the rate of DCI and improved long-term functional outcomes in patients with high modified Fisher grade aSAH. This study also showed a relative benefit of cisternal over intraventricular nicardipine, thereby reducing the number of angioplasties performed in the post-treatment phase. However, these preliminary results should be confirmed with future prospective studies.
- Subjects
CEREBRAL vasospasm; CEREBRAL ischemia; SUBARACHNOID hemorrhage; SPINAL infusions; COHORT analysis; RETROSPECTIVE studies; CONTROL groups
- Publication
Acta Neurochirurgica, 2024, Vol 166, Issue 1, p1
- ISSN
0001-6268
- Publication type
Article
- DOI
10.1007/s00701-024-06023-z